Indirect bronchial hyper‐responsiveness: the coming of age of a specific group of bronchial challenges
2005; Wiley; Volume: 35; Issue: 3 Linguagem: Inglês
10.1111/j.1365-2222.2005.02177.x
ISSN1365-2222
AutoresJan Van Schoor, Ruben Pauwels, G.F. Joos,
Tópico(s)Cystic Fibrosis Research Advances
ResumoClinical & Experimental AllergyVolume 35, Issue 3 p. 250-261 Indirect bronchial hyper-responsiveness: the coming of age of a specific group of bronchial challenges J. Van Schoor, J. Van Schoor Department of Respiratory Diseases, Ghent University Hospital, Ghent, BelgiumSearch for more papers by this authorR. Pauwels, R. Pauwels Department of Respiratory Diseases, Ghent University Hospital, Ghent, BelgiumSearch for more papers by this authorG. Joos, G. Joos Department of Respiratory Diseases, Ghent University Hospital, Ghent, BelgiumSearch for more papers by this author J. Van Schoor, J. Van Schoor Department of Respiratory Diseases, Ghent University Hospital, Ghent, BelgiumSearch for more papers by this authorR. Pauwels, R. Pauwels Department of Respiratory Diseases, Ghent University Hospital, Ghent, BelgiumSearch for more papers by this authorG. Joos, G. Joos Department of Respiratory Diseases, Ghent University Hospital, Ghent, BelgiumSearch for more papers by this author First published: 21 March 2005 https://doi.org/10.1111/j.1365-2222.2005.02177.xCitations: 25 Guy Joos, Department of Respiratory Diseases, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium. E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Global Initiative for Asthma, Revised 2002. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH publication 02-3659A, July 2002. http://www.ginasthma.com 2 Pauwels R. Bronchial hyperresponsiveness. In: AB Kay, ed. Allergy and allergic diseases. Oxford: Blackwell Science Ltd, 1997; 682–91. 3 Sterk PJ. Airway hyperresponsiveness: using bronchial challenge tests in research and management of asthma. J Aerosol Med 2002; 15: 123–9. 4 Joos GF. Do measures of bronchial responsiveness add information in diagnosis and monitoring of patients with asthma? Eur Respir J 2001; 18: 439–41. 5 Brusasco V, Crimi E, Pellegrino R. Airway hyperresponsiveness in asthma: not just a matter of airway inflammation. Thorax 1998; 53: 992–8. 6 Pauwels R, Joos G, Van Der Straeten M. Bronchial hyperresponsiveness is not bronchial hyperresponsiveness is not bronchial asthma. Clin Allergy 1988; 18: 317–21. 7 Van Schoor J, Joos GF, Pauwels RA. Indirect bronchial hyperresponsiveness in asthma: mechanisms, pharmacology and implications for clinical research. Eur Respir J 2000; 16: 514–33. 8 McCoy DE, Schwiebert EM, Karlson KH, Spielman WS, Stanton BA. Identification and function of A1 adenosine receptors in normal and cystic fibrosis human airway epithelial cells. Am J Physiol 1995; 268: C1520–7. 9 Clancy JP, Ruiz FE, Sorscher EJ. Adenosine and its nucleotides activate wild-type and R117H CFTR through an A2B receptor-coupled pathway. Am J Physiol 1999; 276: C361–9. 10 Bai TR, Zhou D, Weir T et al. Substance P (NK1)-and neurokinin A (NK2)-receptor gene expression in inflammatory airway diseases. Am J Physiol 1995; 269: L309–17. 11 Lung CC, Jagels MA, Daffern PJ, Tan EM, Zuraw BL. Induction of human B2 bradykinin receptor mRNA and membrane receptors by IFNγ. Immunopharmacology 1998; 39: 243–53. 12 Joos GF, O'Connor B, ERS Task Force. Indirect airway challenges. Eur Respir J 2003; 21: 1050–68. 13 Tutluoğlu B, Gürbüz N, Atiş S, Abanozlu S, İbiş R, Kanik A. Effects of heparin on hypertonic potassium chloride-induced bronchoconstriction. Ann Pharmacother 2001; 35: 1161–5. 14 Tranfa CME, Vatrella A, Parrella R, Pelaia G, Bariffi F, Marsico SA. Effect of inhaled heparin on water-induced bronchoconstriction in allergic asthmatics. Eur J Clin Pharmacol 2001; 57: 5–9. 15 Rorke S, Jennison S, Jeffs JA, Sampson AP, Arshad H, Holgate ST. Role of cysteinyl leukotrienes in adenosine 5′-monophosphate induced bronchoconstriction in asthma. Thorax 2002; 57: 323–7. 16 Kraan J, Vink-Klooster H, Postma DS. The NK2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma. Clin Exp Allergy 2001; 31: 274–8. 17 Joos G, Van De Velde V, Schelfhout V, Pauwels R. The leukotriene receptor antagonist zafirlukast inhibits neurokinin A-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 2001; 163: A418. 18 Crimi N, Pagano C, Palermo F et al. Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin A-induced bronchoconstriction. J Allergy Clin Immunol 2003; 111: 833–9. 19 Van Schoor J, Joos GF, Pauwels RA. Effect of inhaled fluticasone on bronchial responsiveness to neurokinin A in asthma. Eur Respir J 2002; 19: 997–1002. 20 Reynolds CJ, Togias A, Proud D. Airways hyper-responsiveness to bradykinin and methacholine: effects of inhaled fluticasone. Clin Exp Allergy 2002; 32: 1174–9. 21 Carratù P, Morelli N, Freire AX et al. Effect of zafirlukast on methacholine and ultrasonically nebulized distilled water challenge in patients with mild asthma. Respiration 2003; 70: 249–53. 22 Richter K, Jörres RA, Magnussen H. Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction. Eur Respir J 2000; 15: 693–9. 23 Anderson SD, Brannan J, Spring J et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997; 156: 758–65. 24 Eggleston PA, Kagey-Sobotka A, Lichtenstein LM. A comparison of the osmotic activation of basophils and human lung mast cells. Am Rev Respir Dis 1987; 135: 1043–8. 25 Moloney ED, Griffin S, Burke CM, Poulter LW, O'Sullivan S. Release of inflammatory mediators from eosinophils following a hyperosmolar stimulus. Respir Med 2003; 97: 928–32. 26 Brannan JD, Gulliksson M, Anderson SD, Chew N, Kumlin M. Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur Respir J 2003; 22: 491–6. 27 Currie GP, Haggart K, Brannan JD, Lee DKC, Anderson SD, Lipworth BJ. Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate. Allergy 2003; 58: 762–6. 28 Brannan JD, Anderson SD, Gomes K, King GG, Chan HK, Seale JP. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420–5. 29 Currie GP, Haggart K, Lee DKC et al. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clin Exp Allergy 2003; 33: 783–8. 30 Brannan JD, Anderson SD, Freed R, Leuppi JD, Koskela H, Chan HK. Nedocromil sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects. Am J Respir Crit Care Med 2000; 161: 2096–9. 31 Brannan JD, Koskela H, Anderson SD, Chan HK. Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects. Respirology 2002; 7: 37–44. 32 Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527–52. 33 Young HWJ, Molina JG, Dimina D et al. A3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol 2004; 173: 1380–9. 34 Feoktistov I, Garland EM, Goldstein AE et al. Inhibition of human mast cell activation with the novel selective adenosine A2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX). Biochem Pharmacol 2001; 62: 1163–73. 35 Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, Feoktistov I. Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 2004; 172: 7726–33. 36 Zhong H, Belardinelli L, Maa T, Feoktistov I, Biaggioni I, Zeng D. A2B adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol 2004; 30: 118–25. 37 Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997; 385: 721–5. 38 Suzuki H, Takei M, Nakahata T, Fukamachi H. Inhibitory effect of adenosine on degranulation of human cultured mast cells upon cross-linking with FcɛRI. Biochem Biophys Res Commun 1998; 242: 697–702. 39 Fozard JR, Ellis KM, Villela Dantas MF, Tigani B, Mazzoni L. Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 2002; 438: 183–8. 40 Walker BAM, Jacobson MA, Knight DA et al. Adenosine A3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol 1997; 16: 531–7. 41 Knight D, Zheng X, Rocchini C, Jacobson M, Bai T, Walker B. Adenosine A3 receptor stimulation inhibits migration of human eosinophils. J Leukoc Biol 1997; 62: 465–8. 42 Ezeamuzie CI, Philips E. Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. Br J Pharmacol 1999; 127: 188–94. 43 Joos GF, Pauwels RA. Pro-inflammatory effects of substance P: new perspectives for the treatment of airway diseases? Trends Pharmacol Sci 2000; 21: 131–3. 44 Van Schoor J, Joos GF, Chasson BL, Brouard RJ, Pauwels RA. The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur Respir J 1998; 12: 17–23. 45 Joos G, Schelfhout V, Van De Velde V, Maggi C, Pauwels R. The effect of the tachykinin NK2 receptor antagonist MEN11420 (nepadutant) on neurokinin A-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 2001; 163: A628. 46 Joos GF, Vincken W, Louis R et al. Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J 2004; 23: 76–81. 47 Schelfhout V, Louis R, Lenz W, Pauwels R, Joos G. The triple neurokinin receptor antagonist CS-003 inhibits neurokinin A (NKA)-induced bronchoconstriction in patients with asthma. Eur Respir J 2003; 22 (Suppl. 45): 415s. 48 Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 1999; 103: 232–7. 49 Grönke L, Kanniess F, Holz O, Jörres RA, Magnussen H. The relationship between airway hyper-responsiveness, markers of inflammation and lung function depends on the duration of the asthmatic disease. Clin Exp Allergy 2002; 32: 57–63. 50 Polosa R, Rorke S, Holgate ST. Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Thorax 2002; 57: 649–54. 51 Van Den Berge M, Kerstjens HAM, Postma DS. Provocation with adenosine 5′-monophosphate as a marker of inflammation in asthma, allergic rhinitis and chronic obstructive pulmonary disease. Clin Exp Allergy 2002; 32: 824–30. 52 Van Velzen E, Van Den Bos JW, Benckhuijsen JAW, Van Essel T, De Bruijn R, Aalbers R. Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma. Thorax 1996; 51: 582–4. 53 Van Den Berge M, Meijer RJ, Kerstjens HAM et al. PC20 adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC20 methacholine. Am J Respir Crit Care Med 2001; 163: 1546–50. 54 De Meer G, Heederik D, Postma DS. Bronchial responsiveness to adenosine 5′-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV1. Am J Respir Crit Care Med 2002; 165: 327–31. 55 Van Den Berge M, Kerstjens HAM, Meijer RJ et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 2001; 164: 1127–32. 56 Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001; 14: 141–7. 57 Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346: 1699–705. 58 Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O'Connor BJ. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma. J Allergy Clin Immunol 2002; 110: 603–6. 59 Ketchell RI, Jensen MW, Clarke GW, Allenby MI, O'Connor BJ. Rapid effect of single dose inhaled glucocorticosteroid on airway responsiveness to AMP in asthma is not molecule-dependent. Am J Respir Crit Care Med 2003; 167: A770. 60 Ketchell RI, Clarke GW, Jensen MW, Vos TP, Allenby MI, O'Connor BJ. Time course evaluation of the rapid effect of a single dose of inhaled fluticasone propionate on airway responsiveness to AMP in asthma. Am J Respir Crit Care Med 2003; 167: A770. 61 Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers JWJ. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J 2004; 23: 559–64. 62 Prosperini G, Spicuzza L, Polosa R. Rapid effect of inhaled fluticasone on airway responsiveness to AMP: research implications (letter to the editor+reply). J Allergy Clin Immunol 2003; 111: 1416–7. 63 Taylor DA, Jensen MW, Kanabar V et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine 5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237–43. 64 Prosperini G, Rajakulasingam K, Cacciola RR et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. J Allergy Clin Immunol 2002; 110: 855–61. 65 Hofstra WB, Neijens HJ, Duiverman EJ et al. Dose–responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol 2000; 29: 415–23. 66 O'Connor BJ, Ridge SM, Barnes PJ, Fuller RW. Greater effect of inhaled budesonide on adenosine 5′-monophosphate-induced than on sodium–metabisulphite-induced bronchoconstriction in asthma. Am Rev Respir Dis 1992; 146: 560–4. 67 Doull IJM, Sandall D, Smith S, Schreiber J, Freezer NJ, Holgate ST. Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 5′ monophosphate, methacholine, and bradykinin in symptomatic children with recurrent wheeze. Pediatr Pulmonol 1997; 23: 404–11. 68 Weersink EJM, Douma RR, Postma DS, Koëter GH. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am J Respir Crit Care Med 1997; 155: 1241–6. 69 Fuller RW, Choudry NB, Eriksson G. Action of budesonide on asthmatic bronchial hyperresponsiveness. Effects on directly and indirectly acting bronchoconstrictors. Chest 1991; 100: 670–4. 70 Wiebicke W, Jörres R, Magnussen H. Comparison of the effects of inhaled corticosteroids on the airway response to histamine, methacholine, hyperventilation, and sulfur dioxide in subjects with asthma. J Allergy Clin Immunol 1990; 86: 915–23. 71 Kraan J, Koëter GH, Van Der Mark TW, Sluiter HJ, De Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76: 628–36. 72 Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air hyperventilation in patients with asthma. Thorax 1991; 46: 811–6. 73 Claussen M, Sill V. Influence on non-specific bronchial hyperreactivity to cold air hyperventilation and carbachol by nedocromil and budesonide. Pneumologie 1993; 47: 209–14. 74 Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2-to 5-year-old asthmatic children. Am J Respir Crit Care Med 2000; 162: 1500–6. 75 Du Toit JI, Anderson SD, Jenkins CR, Woolcock AJ, Rodwell LT. Airway responsiveness in asthma: bronchial challenge with histamine and 4.5% sodium chloride before and after budesonide. Allergy Asthma Proc 1997; 18: 7–14. 76 Groot CAR, Lammers JWJ, Molema J, Festen J, Van Herwaarden CLA. Effect of inhaled beclomethasone and nedocromil sodium on bronchial hyperresponsiveness to histamine and distilled water. Eur Respir J 1992; 5: 1075–82. 77 Bootsma GP, Dekhuijzen PNR, Festen J, Mulder PGH, Van Herwaarden CLA. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax 1995; 50: 1044–50. 78 Roisman GL, Lacronique JG, Desmazes-Dufeu N, Carré C, Le Cae A, Dusser DJ. Airway responsiveness to bradykinin is related to eosinophilic inflammation in asthma. Am J Respir Crit Care Med 1996; 153: 381–90. 79 Polosa R, Louis R, Cacciola R, Prosperini G, Crimi N, Djukanovic R. Sputum eosinophilia is more closely associated with airway responsiveness to bradykinin than methacholine in asthma. Eur Respir J 1998; 12: 551–6. 80 Berman AR, Togias AG, Skloot G, Proud D. Allergen-induced hyperresponsiveness to bradykinin is more pronounced than that to methacholine. J Appl Physiol 1995; 78: 1844–52. 81 Van Rensen ELJ, Straathof KCM, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999; 54: 403–8. 82 Carpentiere G, Castello F, Marino S. Effect of beclomethasone dipropionate on the bronchial responsiveness to propranolol in asthmatics. Chest 1990; 98: 263–5. 83 Van Grunsven PM, Van Schayck CP, Molema J, Akkermans RP, Van Weel C. Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis. Thorax 1999; 54: 316–22. 84 Sovijärvi ARA, Haahtela T, Ekroos HJ et al. Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment. Thorax 2003; 58: 500–4. 85 Kerrebijn KF, Van Essen-Zandvliet EEM, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653–9. 86 Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142: 832–6. 87 Kerstjens HAM, Brand PLP, Dutch chronic non-specific lung disease study group et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992; 327: 1413–9. 88 Van Essen-Zandvliet EE, Hughes MD, Dutch chronic non-specific lung disease study group et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992; 146: 547–54. 89 Sont JK, Willems LNA, AMPUL study group. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999; 159: 1043–51. 90 Ward C, Pais M, Bish R et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57: 309–16. 91 Kips JC, Pauwels RA. Airway wall remodeling: does it occur and what does it mean? Clin Exp Allergy 1999; 29: 1457–66. 92 Chetta A, Foresi A, Del Donno M et al. Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. Am J Respir Crit Care Med 1996; 153: 910–7. 93 Douma WR, Kerstjens HAM, Dutch chronic nonspecific lung disease study group. Initial improvements in lung function and bronchial hyperresponsiveness are maintained during 5 years of treatment with inhaled beclomethasone dipropionate and terbutaline. Chest 2002; 121: 151–7. 94 Koh YY, Sun YH, Lim HS, Kim CK, Hong SJ. Effect of inhaled budesonide on bronchial hyperresponsiveness in adolescents with clinical remission of asthma. Chest 2001; 120: 1140–6. 95 Djukanović R, Wilson JW, Britten KM et al. Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am Rev Respir Dis 1990; 142: 863–71. 96 Sont JK, Van Krieken JHJM, Evertse CE, Hooijer R, Willems LNA, Sterk PJ. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996; 51: 496–502. 97 Boulet LP, Turcotte H, Brochu A. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest 1994; 105: 1024–31. 98 Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Kerrebijn KF, the Dutch chronic non-specific lung disease study group. Remission of childhood asthma after long-term treatment with an inhaled corticosteroid: can it be achieved? Eur Respir J 1994; 7: 63–8. 99 Cockcroft DW. How best to measure airway responsiveness. Am J Respir Crit Care Med 2001; 163: 1514–5. 100 Holgate ST. Adenosine provocation: a new test for allergic type airway inflammation. Am J Respir Crit Care Med 2002; 165: 317–9. 101 Grashoff WFH, Sont JK, Sterk PJ et al. Chronic obstructive pulmonary disease. Role of bronchiolar mast cells and macrophages. Am J Pathol 1997; 151: 1785–90. 102 Louis RE, Cataldo D, Buckley MG et al. Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease. Eur Respir J 2002; 20: 325–31. 103 Sterk PJ, Fabbri LM, Quanjer PhH et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests. European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J 1993; 6 (Suppl. 16): 53–83. 104 American Thoracic Society. Guidelines for methacholine and exercise challenge testing – 1999. Am J Respir Crit Care Med 2000; 161: 309–29. 105 Anderson SD, Brannan J, Trevillion L, Young IH. Lung function and bronchial provocation tests for intending divers with a history of asthma. SPUMS J 1995; 25: 233–48. 106 British Thoracic Society Guidelines on Respiratory Aspects of Fitness for Diving. British Thoracic Society Fitness to Dive Group, a Subgroup of the British Thoracic Society Standards of Care Committee. Thorax 2003; 58: 3–13. 107 Djukanović R, Sterk PJ, Fahy JV, Hargreave FE, ERS Task Force Standardised methodology of sputum induction and processing. Eur Respir J 2002; 20 (Suppl. 37): 1s–55s. 108 Van Rensen ELJ, Hiemstra PS, Rabe KF, Sterk PJ. Assessment of microvascular leakage via sputum induction. The role of substance P and neurokinin A in patients with asthma. Am J Respir Crit Care Med 2002; 165: 1275–9. 109 Leuppi JD, Brannan JD, Anderson SD. Bronchial provocation tests: the rationale for using inhaled mannitol as a test for airway hyperresponsiveness. Swiss Med Wkly 2002; 132: 151–8. 110 McKenzie DC, Stewart IB, Fitch KD. The asthmatic athlete, inhaled beta agonists, and performance. Clin J Sport Med 2002; 12: 225–8. 111 Weiler JM. Why must Olympic athletes prove that they have asthma to be permitted to take inhaled β2-agonists? J Allergy Clin Immunol 2003; 111: 36–7. 112 International Olympic Medical Commission., Beta2-adrenoceptor agonists and the Olympic Winter Games in Salt Lake City. http://www.olympic.org 113 Holzer K, Anderson SD, Douglass J. Exercise in elite summer athletes: challenges for diagnosis. J Allergy Clin Immunol 2002; 110: 374–80. 114 Anderson SD, Argyros GJ, Magnussen H, Holzer K. Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction. Br J Sports Med 2001; 35: 344–7. 115 Holzer K, Anderson SD, Chan HK, Douglass J. Mannitol as a challenge test to identify exercise-induced bronchoconstricion in elite athletes. Am J Respir Crit Care Med 2003; 167: 534–7. 116 Jammes Y, Burnet H, Cosson P, Lucciano M. Bronchomotor response to cold air or helium-oxygen at normal and high ambient pressures. Undersea Biomed Res 1988; 15: 179–92. 117 Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–21. 118 Anderson SD, Brannan JD, Chan HK. Use of aerosols for bronchial provocation testing in the laboratory: where we have been and where we are going. J Aerosol Med 2002; 15: 313–24. Citing Literature Volume35, Issue3March 2005Pages 250-261 ReferencesRelatedInformation
Referência(s)